title: Effects of 17 beta-estradiol and progesterone on growth-factor-induced proliferation and migration in human female aortic smooth muscle cells in vitro.
abstract: OBJECTIVE
  The significantly low prevalence of atherosclerotic cardiovascular disease in premenopausal women has been noted, and postmenopausal hormone replacement therapy (HRT) is associated with protection from this disease. The aim of this study was to investigate the effects of estrogen and progestin on growth-factor-induced vascular smooth muscle cell (VSMC) proliferation and migration in vitro.
  
  
  METHODS
  Two cell lines of human female aortic smooth muscle cells (AOSMCs) were used for the study. DNA synthesis was evaluated by [3H]thymidine incorporation into cells. Migration assay was performed using modified Boyden chambers.
  
  
  RESULTS
  The presence of estrogen receptors was determined by Western and Northern blot analyses. [3H]Thymidine incorporation into AOSMCs was induced by 10 ng/ml EGF alone, the combination of 10 ng/ml EGF with 2 ng/ml b-FGF-induced and 1 nM PDGF-BB alone. Migration of AOSMCs was induced by PDGF-BB. Since 17 beta-estradiol (E2, 10(-9) M approximately 10(-6) M) inhibited the [3H]thymidine incorporation into AOSMCs stimulated by above mitogens and the 1 nM PDGF-BB-induced AOSMC migration in a dose-dependent manner, estrone (E1), estriol (E3) and progesterone (P) had no significant effects. The combination of P (10(-9) M approximately 10(-6) M) did not show any effect on these inhibitory effects of 10(-7) M E2. Preincubation of AOSMCs with the anti-estrogenic agent, tamoxifen (10(-6) M), significantly antagonized these inhibitory effects of 10(-7) M E2.
  
  
  CONCLUSIONS
  These findings suggest that the inhibitory effect of E2 on VSMC proliferation and migration might be one of the factors involved in the decreased incidence of atherosclerotic cardiovascular disease in premenopausal women and postmenopausal HRT, and P might not affect these estrogenic responses.
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Mizuno
authors.forename: Y
authors.initials: Y
authors.lastname: Ino
authors.forename: M
authors.initials: M
authors.lastname: Okada
authors.forename: F
authors.initials: F
authors.lastname: Kikkawa
authors.forename: S
authors.initials: S
authors.lastname: Mizutani
authors.forename: Y
authors.initials: Y
authors.lastname: Tomoda
mesh_terms: D000328:Adult; D001011:Aorta / Q000166:cytology / Q000187:drug effects*; D000077214:Becaplermin; D015152:Blotting, Northern; D015153:Blotting, Western; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D002478:Cells, Cultured; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D012739:Gonadal Steroid Hormones / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D011374:Progesterone / Q000494:pharmacology; D020574:Proto-Oncogene Proteins c-sis; D011960:Receptors, Estrogen / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology; D013629:Tamoxifen / Q000494:pharmacology
chemical_list: D012739:Gonadal Steroid Hormones; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011960:Receptors, Estrogen; D011994:Recombinant Proteins; D013629:Tamoxifen; D000077214:Becaplermin; D011374:Progesterone; D004958:Estradiol